Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.
Pulmatrix launches iSPERSE, a novel inhaled dry powder drug delivery platform